Biotech Industry · global
Reducing Fat While Preserving Lean Tissue: Roche Secures Global License to Rona’s ALK7 RNAi Therapy
A licensing deal worth up to $1.16 billion turns obesity drug development’s attention to fat cells themselves. The concept of selectively reducing visceral fat while preserving lean tissue still awaits validation in human studies.
The next question in obesity treatment is what the body actually loses when weight drops. Roche has secured an exclusive global license to an experimental RNA interference (RNAi) therapy from Rona Therapeutics that targets ALK7, seeking to explore whether the mechanisms that regulate fat cells could offer a way to reduce fat while preserving lean tissue.
Rona announced the agreement on October 13 for a candidate therapy for obesity and metabolic diseases. The deal includes up to $100 million in upfront and near-term milestone payments, a further $1.06 billion in potential payments contingent on development, regulatory and commercialization goals, and tiered royalties on global net sales. The $1.16 billion figure is therefore the maximum potential payment, with most of the amount still subject to conditions being met.
Descriptions of the initial payment differ slightly across reports: Reuters described the $100 million as an upfront payment, while Rona’s original announcement and AWP’s report both specified that it is the combined maximum for upfront and near-term milestone payments. The announcement did not break down the two amounts, so it does not establish that Roche has already paid $100 million in a single payment.
The scientific concept behind the therapy centers on ALK7, which is expressed primarily in fat cells. Rona said this signaling pathway is involved in lipid storage, fat breakdown and energy balance, and that human genetic studies have linked lower ALK7 activity to more favorable fat distribution and metabolic characteristics. The candidate uses RNAi technology alongside the company’s extrahepatic delivery platform, with the aim of reducing ALK7 expression in fat cells; however, the announcement provided no data on delivery efficiency or pharmacological effects in humans.
The potential advantage proposed by Rona is the selective reduction of visceral fat and other ectopic fat while preserving lean tissue. AWP also noted that this approach, which acts directly on fat cells, could complement incretin-based obesity therapies. However, lean tissue is not equivalent to muscle, and the concept cannot currently be interpreted as proven to preserve muscle strength or provide additional efficacy when combined with existing drugs.
The announcement establishes a licensing and development collaboration, but does not yet present clinical results. The publicly disclosed information did not specify the candidate’s trial stage or provide participant numbers, the extent of fat reduction, the duration of efficacy or safety results. Roche’s investment provides resources to advance this development approach; whether it can improve fat distribution in humans while balancing metabolic benefits and safety during long-term treatment remains a question for subsequent studies.